350,000 Shares in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Acquired by Boxer Capital Management LLC

Boxer Capital Management LLC acquired a new position in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 350,000 shares of the company's stock, valued at approximately $7,483,000. Boxer Capital Management LLC owned approximately 2.33% of Jasper Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rhumbline Advisers grew its position in shares of Jasper Therapeutics by 12.6% during the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company's stock valued at $316,000 after purchasing an additional 1,652 shares in the last quarter. Barclays PLC boosted its position in Jasper Therapeutics by 13.6% during the fourth quarter. Barclays PLC now owns 18,334 shares of the company's stock valued at $392,000 after purchasing an additional 2,188 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Jasper Therapeutics by 13.9% in the 4th quarter. Wellington Management Group LLP now owns 27,069 shares of the company's stock worth $579,000 after purchasing an additional 3,310 shares in the last quarter. Wells Fargo & Company MN grew its stake in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after buying an additional 3,828 shares during the last quarter. Finally, Rock Springs Capital Management LP boosted its holdings in Jasper Therapeutics by 0.9% in the fourth quarter. Rock Springs Capital Management LP now owns 463,088 shares of the company's stock worth $9,901,000 after acquiring an additional 4,000 shares in the last quarter. Hedge funds and other institutional investors own 79.85% of the company's stock.

Jasper Therapeutics Stock Performance

Shares of JSPR traded down $0.22 during mid-day trading on Wednesday, hitting $4.53. 97,477 shares of the company's stock were exchanged, compared to its average volume of 287,360. The company has a market cap of $67.97 million, a price-to-earnings ratio of -0.95 and a beta of 2.74. The stock's 50-day moving average is $4.74 and its 200-day moving average is $11.82. Jasper Therapeutics, Inc. has a fifty-two week low of $3.13 and a fifty-two week high of $26.84.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.35). As a group, equities research analysts anticipate that Jasper Therapeutics, Inc. will post -4.47 EPS for the current year.

Analyst Ratings Changes

JSPR has been the topic of several research analyst reports. UBS Group started coverage on shares of Jasper Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $38.00 target price on the stock. Royal Bank of Canada lowered their price target on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research report on Thursday, January 9th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $62.50.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.